SCHEMBL24257746

SCHEMBL24257746

CCOC(=O)CNC(=O)c1ncc(-c2cnn(C3CCOCC3)c2)c(C)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.40
PRKAB2 O43741 1/20 0.40
CSF1R P07333 1/20 0.40
LYN P07948 1/20 0.40
TGFBR1 P36897 1/20 0.40
PRKAG1 P54619 1/20 0.40
SIK1 P57059 1/20 0.40
PRKAA1 Q13131 1/20 0.40
SIK2 Q9H0K1 1/20 0.40
SIK3 Q9Y2K2 1/20 0.40
IRAK4 Q9NWZ3 3/20 0.39
FGFR1 P11362 2/20 0.37
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TRPV1 Q8NER1 1/20 0.35
KCNJ5 P48544 1/20 0.35
USP28 Q96RU2 1/20 0.35
USP25 Q9UHP3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257611 0.89 IRAK4 (0.41) ABL1PRKAB2CSF1RLYNTGFBR1
SCHEMBL24257786 0.85 MET (0.44) FGFR1LMNAJAK3BTKMET
SCHEMBL30546843 0.85 MET (0.44) FGFR1LMNAJAK3BTKMET
SCHEMBL24257594 0.85 IRAK4 (0.38) ABL1PRKAB2CSF1RLYNTGFBR1
SCHEMBL29248985 0.81 IRAK4 (0.46) IRAK4FGFR1KCNJ5MKNK1LRRK2
SCHEMBL26259620 0.80 EGLN1 (0.44) JAK2LRRK2FLT1
SCHEMBL24257797 0.79 HSP90AA1 (0.41) ALDH1A1LMNAHPGDHSD17B10JAK2
SCHEMBL24257770 0.77 ALDH1A1 (0.39) ALDH1A1LMNAHPGDHSD17B10JAK2
SCHEMBL24257699 0.76 HPGD (0.44) ALDH1A1LMNAHPGDHSD17B10
SCHEMBL24257505 0.76 TNK2 (0.45) IRAK4FGFR1LMNAJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 ABL1 1142/4885PRKAB2 3124/4885CSF1R 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.